# ROCKWELL MEDICAL, INC. (RMTI) · Edgar & Edgarette company card

> Rockwell Medical, Inc. (RMTI) saw revenue fall 31.8% in FY2025 to $69 million, operating margin -6.8% against a -3.8% median for pharmaceutical preparations, equity 64.7% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1041024 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/RMTI) · [JSON](https://www.pops4.com/boards/company/RMTI.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $69M |
| Revenue growth, 1 year | -31.8% |
| Revenue growth per year | 2.8% |
| Operating margin | -6.8% (prior year 0.6%) |
| Net margin | -7.7% |
| Operating cash flow | −$659,000 |
| Capital spending | $542,000 |
| Free cash flow | −$1M |
| Cash | $11M |
| Long-term debt | $9M |
| Total assets | $57M |
| Total equity | $37M |
| Equity ÷ assets | 64.7% |
| Return on equity | -14.4% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -18.33 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Beneish M: -2.81 (below the −1.78 line)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -6.8% in FY2025; revenue is hard to predict: its 80% range is ±41%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $69.3M (FY2025), total debt $8.8M. Experience: revenue down 31.8% on the year, up 2.8% a year over 4 years; operating margin -6.8%, down from 0.6%. Soundness: equity 64.7% of assets, return on equity -14.4%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $36.1M and $85.8M next year (method v4.1: its own 6-year record of growth weighed at 63% against $50M–100M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $37.3M to $83.2M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -6.8% against a -3.8% median; growth -31.8% against 13.7%.

Range logged 2026-11-01, receipt 4821b9defe864be3, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 1, latest 2026-05-08 ([filing](https://www.sec.gov/Archives/edgar/data/1041024/000162828026032987/0001628280-26-032987-index.htm))
- Item 5.02 Director or officer change: 1, latest 2025-11-18 ([filing](https://www.sec.gov/Archives/edgar/data/1041024/000110465925113452/0001104659-25-113452-index.htm))

## Recent filings

- 8-K · filed 2026-11-03 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1041024/000110465926122103/0001104659-26-122103-index.htm)
- 8-K · filed 2026-08-13 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1041024/000162828026056470/0001628280-26-056470-index.htm)
- 10-Q · filed 2026-08-13 · [filing](https://www.sec.gov/Archives/edgar/data/1041024/000162828026056461/0001628280-26-056461-index.htm)
- 8-K · filed 2026-08-13 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1041024/000162828026056454/0001628280-26-056454-index.htm)
- 8-K · filed 2026-07-20 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1041024/000162828026048752/0001628280-26-048752-index.htm)
- 8-K · filed 2026-06-29 · 3.03 Material Modifications to Rights of Security Holders; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1041024/000162828026045866/0001628280-26-045866-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001041024.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1041024

## Cite

POPS4, Edgar & Edgarette: ROCKWELL MEDICAL, INC. (RMTI) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/RMTI. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.